Lansdale, PA, United States of America

Edward J Cragoe, Jr

This inventor holds 174 USPTO granted patents, primarily in Pharmaceutical Compounds (CPC class 424250). Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Merck Frosst Canada, Inc.. Active years: 1976-1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Edward J Cragoe, Jr. Retrieved from https://idiyas.com/inventor/edward-j-cragoe-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.4

ph-index = 37

Forward Citations = 5,119(Granted Patents)

Forward Citations (Not Self Cited) = 4,916(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:


Years Active: 1976-1989

Loading Chart...
Areas of Expertise:
Sickle Cell Anemia
Cholesterol Synthesis
Anti-Asthmatic
Dibenzoxathiepin
Pharmaceutical Compositions
Prostaglandin Antagonists
Glycolic Inhibitors
Indanones
Alkanoic Acids
Pyranone Inhibitors
Dihydro Indenes
Tetrahydrofluorenes
174 patents (USPTO):Explore Patents

Title: Edward J Cragoe, Jr.: Pioneer in Brain Injury Treatment and Prevention

Introduction:

Edward J Cragoe, Jr., an esteemed innovator and inventor based in Lansdale, PA, has made significant contributions to the field of medicine through his groundbreaking patents. With a remarkable total of 174 patents, Cragoe's work focuses primarily on the development of novel compounds for the treatment and prevention of brain injuries and related conditions. Let us delve deeper into Cragoe's latest patents, career highlights, collaborations, and his invaluable contributions to the medical field.

Latest Patents:

Cragoe's recent patents include the inventions of "5,6-dichloro-3-oxo-9.alpha.-propyl-2,3,9,9.alpha.-tetrahydrofluoren-7-yl)]alkanoic acids and alkanimidamides, their derivatives, and their salts" and "[5,6-dichloro-3-oxo-9,9a-disubstituted-2,3,9,9a-tetrahydro-fluoren-7-yl)oxy]alkanoic acids and alkanimidamides, their derivatives, and their salts." These compounds demonstrate potential in the treatment and prevention of brain injuries caused by various factors, including head trauma, stroke, cardiac arrest, and cerebral tumors, among others.

Career Highlights:

Edward J Cragoe, Jr. has held key positions in renowned pharmaceutical companies throughout his career. He has made notable contributions to both Merck & Company, Inc. and Merck Sharp & Dohme Corporation. As an influential figure in the field, Cragoe has been instrumental in advancing research and development efforts aimed at improving medical treatments and interventions for brain injuries.

Collaborations:

Cragoe's remarkable contributions were not accomplished in isolation. He has worked alongside esteemed colleagues, such as Otto W Woltersdorf, Jr., and Clarence S Rooney. These collaborative efforts have allowed the team to capitalize on diverse expertise and foster innovation in the field of brain injury treatment and prevention.

Conclusion:

Edward J Cragoe, Jr., with an extensive background in pharmaceutical innovation, has made significant strides in the area of brain injury treatment and prevention. Boasting an impressive 174 patents, including his latest inventions aimed at combating brain injuries, Cragoe's groundbreaking work has the potential to revolutionize the medical landscape. By collaborating with esteemed peers and working with prominent pharmaceutical companies, Cragoe has ensured that his inventions become tangible solutions that positively impact patients' lives. As his work continues to inspire and drive advancements in the medical field, Edward J Cragoe, Jr. establishes himself as a leading figure in the fight against brain injuries.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…